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Background: Therapy for stroke prevention in older persons with atrial fibrillation (AF) is underutilized despite
evidence to support its effectiveness. To prevent stroke in this high-risk population, antithrombotic treatment is
necessary. Given the challenges and inherent risks of antithrombotic therapy, decision-making is particularly
complex for clinicians, necessitating comprehensive risk:benefit assessments. Targeted interventions are urgently
needed to support clinicians in this context; the Computerized Antithrombotic Risk Assessment Tool (CARAT) offers
a unique approach to this clinical problem.
Methods/design: This study (a prospective, cluster-randomized controlled clinical trial) will be conducted across
selected regions in the state of New South Wales, Australia. Fifty GPs will be randomized to either the ‘intervention’
or ‘control’ arm, with each GP recruiting 10 patients (aged ≥65 with AF); target sample size is 500 patients. GPs in
the intervention arm will use CARAT during routine patient consultations to: assess risk factors for stroke, bleeding and
medication misadventure; quantify the risk/benefit ratio of antithrombotic treatment, identify the recommended
therapy, and decide on the treatment course, for an individual patient. CARAT will be applied by the GP at baseline and
repeated at 12 months to identify any changes to treatment requirements. At baseline, the participant (patients and
GPs) characteristics will be recorded, as well as relevant practice and clinical parameters. Patient follow up will occur at
1, 6, and 12 months via telephone interview to identify changes to therapy, medication side effects, or clinical events.
Discussion: This project tests the utility of a novel decision support tool (CARAT) in improving the use of preventative
therapy to reduce the significant burden of stroke. Importantly, it targets the interface of patient care (general practice),
addresses the at-risk population, evaluates clinical outcomes, and offers a tool that may be sustainable via integration
into prescribing software and primary care services. GP support and guidance in identifying at risk patients for the
appropriate selection of therapy is widely acknowledged. This trial will evaluate the impact of CARAT on the
prescription of antithrombotic therapy, its longer-term impact on clinical outcomes including stroke and bleeding,
and clinicians perceived utility of CARAT in practice.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000060741.
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Age, atrial fibrillation, and stroke
Stroke accounts for significant morbidity and mortality
globally every year, including in Australia (where this
study is being conducted) [1]. Advancing age is a key
non-modifiable risk factor for stroke, and this is import-
ant to recognize given that 80% of stroke sufferers are
over 60 years old and that 80% of stroke-related deaths
occur in those over 75 years old [1]. As the population
ages the incidence of stroke rises, doubling the disability
burden by the year 2031 [2].
Atrial Fibrillation (AF), commonly dubbed the ‘arrhythmia
of the millennium’, is the commonest irregular heart
rhythm encountered in clinical practice, and is report-
edly most prevalent in the elderly population [3,4]. It is
infamous for its propensity to form stroke-causing
thrombi in the heart chambers (atria) that can embolize to
other parts of the body; these thrombo-emboli can
subsequently occlude the blood vessels and disrupt the
circulatory supply through to the brain, causing ischemia,
i.e., stroke [5].
Patients with AF have at least a 5 to 6-fold increased risk
of stroke [6], and in the elderly the proportion of stroke at-
tributable to AF is at least one-third [7-9]. Independently,
‘old’ age and chronic AF are major risk factors for stroke
but, unfortunately, both are irreversible. This complex of
factors significantly compounds the risk of stroke in older
people with AF, and for this reason, stroke prevention in
this population is now recognized as a global health
priority.
Stroke prevention therapy
To date, numerous large clinical trials and meta-analyses
have provided convincing evidence that antithrombotics
(anti-clotting agents) can prevent stroke in patients with
AF [10,11]. Historically, antithrombotic therapy has been
reliant on two key agents: warfarin (anticoagulant) and
aspirin (antiplatelet). Warfarin has been reported to re-
duce the risk of stroke by approximately two-thirds,
whilst aspirin is less effective, reducing the risk by about
20% [10].
Underutilization of preventative therapies
Although highly effective antithrombotic medicines, specif-
ically warfarin, are significantly underutilized in practice
[12-16]; data from local Australian practice shows that this
is especially true in the target at-risk older population, even
in the absence of apparent contraindications [12]. A fear of
side effects underpins this [17,18] because antithrombotics
inherently increase the potential for bleeding. Therapy,
therefore, requires careful patient selection, close patient
monitoring (via blood tests), and regular dosage adjust-
ment. This is particularly true for warfarin, as pharmaco-
logical characteristics render its use more challenging inpatients with multiple medical comorbidities and/or poly-
pharmacy (e.g., elderly) [19].
Unfortunately, the inconvenience of therapy has led
some clinicians to cite “old age” per se as a contraindica-
tion to treatment without further risk/benefit assessment,
leading to the underutilization of warfarin. In older people
the risk of stroke is high but so too may be the risk of
medication misadventure [20], giving clinicians a platform
to question whether initiating life-saving anti-coagulant
therapy is done at the expense of causing potentially life-
threatening side-effects.
In more recent times, clinicians have been awaiting
the availability of alternative agents (so-called ‘novel’
oral anticoagulants - NOACs) to overcome some of
these known challenges of warfarin therapy. Whilst the
newer agents present viable, effective treatment alterna-
tives (e.g., dabigatran, rivaroxaban, apixaban), they are
not without their own inherent risks [21]. Furthermore,
the cost-effectiveness of these agents must be carefully
considered, before widespread use in the at-risk popula-
tion can be supported. For this reason, decision-making
regarding stroke prevention in AF is still largely focused
on the selection of warfarin (anticoagulant) versus as-
pirin (antiplatelet) therapy, and has been highlighted
again in the recent Australian Government Review into
Anticoagulation Therapies for Atrial Fibrillation [22]. In
any case, the expanding armamentarium of treatment
options for stroke prevention in AF has added to the
complexity of decision-making in this clinical context.Optimizing stroke prevention in general practice
Primary care is the key to optimal stroke prevention,
and past guidelines have stated that “General Practi-
tioners … are the key to better stroke prevention. What is
needed is proactive opportunistic screening and risk
management, and prompt action for two groups of pa-
tients: those with stroke/TIA symptoms and those with
atrial fibrillation” (National Health and Medical Re-
search Council, NHMRC; (23)).
Although it is widely recognized that general practi-
tioners (GPs) are well placed to facilitate stroke prevention
[23], the EXAMINE-AF study conceded that management
by a GP, compared to a cardiologist, continues to be a sig-
nificant predictor for the underutilization of warfarin, even
in high-risk patients with a prior history of stroke [24]. A
national survey of Australian GPs reinforces that there is a
need to support GPs in quantifying stroke risk versus
bleeding risk, to eliminate misperceptions about risk and
to reduce anxiety about “acts of commission” [18]. Careful
patient selection via risk/benefit assessment is integral to
decision-making here, but guidelines per se are ineffective
as they fail to demonstrate how evidence can be actioned
in individual patients [13,25].
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comprehensive risk assessment process can significantly
improve the utilization of therapy [26]. Using evidence-
based algorithms to facilitate the systematic review of
individual stroke risk and bleeding risk (taking into ac-
count medical, functional, cognitive, medication-related,
and social factors), the use of antithrombotics increased
(59.6% versus 81.2%, p < 0.001). Overall, 36% of patients
required changes to their existing therapy, with 76.9% of
these being ‘upgrades’ to more effective treatment. Fol-
lowing the success of this intervention, the founding risk
assessment algorithm has been integrated into a key
Clinical Indicator (Indicator 1.6) in the NSW Thera-
peutic Advisory Group’s (TAG) “Indicators for Quality
Use of Medicines in Australian Hospitals” [27].
Although highly effective, a limitation of the above ap-
proach is the reliance on a paper-based process that cannot
be linked into an increasingly electronic and online health
system. In response to clinician feedback, the CARAT, an
electronic (web-based) Computerized Antithrombotic Risk
Assessment Tool, has been developed to aid clinicians in
selecting appropriate antithrombotic therapy in older per-
sons with AF. Unlike paper-based guidelines, it facilitates a
systematic review of risk factors and calculates the esti-
mated risk versus benefit of therapy in an individual patient.
The CARAT inputs are modeled on those used in a previ-
ous study [26] and current evidence [28].
An exploratory study has yielded feedback from clini-
cians highlighting the potential utility of CARAT in prac-
tice [29]. Overall the majority of clinicians: are satisfied
with CARAT’s format (94%); agree with its recommenda-
tions when applied to patient cases (72%); and agree with
its estimate of stroke and bleeding risk (>66%). Most
(63%) clinicians (geriatricians, cardiologists, neurologists,
hematologists) positively indicated that CARAT was at
least “somewhat useful” for their clinical practice with 22%
indicating it was ‘very useful’ because:
“Highlights functional elements that need to be
considered. Multifactorial review is essential”“Warfarin is not a lifelong decision; people can fail a
trial of anticoagulation but embolic stroke is
irreversible [this tool helps re-focus away from bleeding
risk, highlights stroke risk]”“May be useful for a less experienced doctor”“This tool should ideally be applied in ED and result
should go to local medical officer”“Rapid calculation of risks is very useful”“Bleeding risk assessment section is very useful”Whilst these findings are encouraging, the utility of the
tool is expected to be far greater in general practice given
its focus on chronic disease prevention and management,
and where previous studies have highlighted a poor dis-
semination of evidence to support GPs’ decision-making
[17]. Indeed, there is scope for improving the use of ther-
apy through such a tool; preliminary data evaluating the
CARAT as a screening tool shows that, in a cohort of
older patients (≥65 years) with AF, less than half (44%) of
those indicated for warfarin (N = 126) were prescribed it;
in those in whom warfarin was NOT indicated (i.e., un-
favorable risk: benefit profile), 46% of patients were actually
prescribed it. Furthermore, 12% of patients did not receive
any preventative therapy at all, despite it being indicated
and the absence of contraindications (30). The National
Institute of Clinical Studies acknowledges our earlier find-
ings and those of others, supporting the crucial need for
improving stroke risk assessment and provision of infor-
mation to GPs [30].
Study aim and objectives
Optimizing stroke prevention in general practice requires
targeted interventions to address the critical need for im-
proving stroke risk assessment and provision of informa-
tion to GPs [30]. Therefore, this study will undertake a
trial of the CARAT in general practice as a targeted inter-
vention to assist clinicians in selecting appropriate therapy
for stroke prevention in older persons with AF.
The Specific Objectives of this study are to:
1. evaluate the impact of CARAT on the prescription
of antithrombotic therapy post-application of the
tool, including initiation of, and changes to, therapy
(quantitative data analysis)
2. measure the longer-term impact of CARAT on
clinical outcomes (strokes, bleeds) (quantitative
data analysis)
3. gauge clinician feedback regarding CARAT in
terms of its perceived utility in practice
(qualitative data analysis)
Hypotheses
Application of the CARAT in general practice will im-
prove the utilization of appropriate antithrombotic (anti-
clotting) therapy in older persons with AF. Further, it
will improve clinical outcomes in older persons with AF,
specifically in terms of reducing the incidence of stroke
and bleeding events.
Methods and design
Study design and setting
Design
This study is a prospective cluster-randomized con-
trolled clinical trial (CRT) utilizing an innovative online
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Risk Assessment Tool - CARAT (Trial Registration:
ACTRN12613000060741). Approval for the conduct of
the study has been granted by the Human Research
Ethics Committees of the participating institutions:
University of Technology Sydney; University of Sydney;
and University of Newcastle. Additionally, support
from the participating Divisions of General Practice
has also been granted: Hunter Urban (i.e., GP Access),
Hunter Rural, Central Coast, and Hornsby Ku-ring-gai
divisions.
Setting
The study will be conducted in Australia, in the state of
New South Wales (NSW). Specifically, the study will be
undertaken within 4 Divisions of General Practice that ac-
commodate a high proportion of older patients and which
represent persons from diverse backgrounds in terms
of socioeconomics, health status, and access to health ser-
vices: City-Metropolitan (Northern Suburbs), Coastal-Region
(Central Coast, NSW), Regional-Urban (Hunter Region,
Newcastle metropolitan area), and Regional-Rural (Hunter
Region, rural areas).
Participants
Fifty GPs will be recruited and randomized to either
the intervention (CARAT) arm or control (usual care)
arm to recruit a total 500 elderly patients with AF
(Figure 1), i.e., 25 GPs will be recruited to each of the
two study arms. Randomization will occur at the GP
level at the time of recruitment [31], not at the division or
regional level, to facilitate comparison over a cross-
section of GPs and patients, and to negate any regional
confounders.
The sample size has been estimated based on previous
local data [12,26]. Estimated changes to the utilization of
therapy are founded in data from previous studies where
only 35% of high-risk AF patients were prescribed war-
farin, where interventions have demonstrated upgrades
in therapy in poorly protected patients by at least 15% to
23% [12,26]. Taking into account any clustering effects
(a prior intra-cluster correlation/ICC = 0.03), and a par-
ticipant drop-out rate of up to 20%, a minimum of 25
GPs and 250 patients are required to achieve statistically
significant results [32,33].
Participant recruitment and eligibility
a) General Practitioner
GPs will be recruited via invitational letters, promo-
tional flyers inside newsletters, and presentations during
education events, coordinated by the Divisions of Gen-
eral Practice. Eligible GPs include those who: are practicing in one site at a general practice
surgery and not across multiple sites or surgeries;
 practice in the specified Divisions of GP;
 provide informed written consent to participate in
the study.
Once recruited, the GPs will be randomly allocated to a
study arm (‘intervention’ versus ‘control’) using computer-
generated random allocation number sequences. The
process will be coordinated centrally by a Chief Investiga-
tor independently of GP recruitment, intervention imple-
mentation, or data collection processes, and who will
conceal the initial allocation process from project officers
(e.g., allocation numbers will be placed in sealed, serially
coded envelopes, and housed in a locked cabinet).
b) Patient
Patients will be recruited by their GPs during routine
care over a 3-month period. Each GP will be required to
recruit 10 patients that meet the following study inclu-
sion criteria:
 are aged ≥ 65 years;
 have a diagnosis of chronic (persistent) AF, whether
new or pre-existing and irrespective of the anti-
thrombotic therapy prescribed at the time of
recruitment;
 provide informed written consent to participate in the
study and agree to be followed-up via telephone inter-
view over a 12 month period (1,6 and 12 months).
Patients will be informed that all personal information
is de-identified and that they may withdraw from the
study at any time without any negative consequences.
Minimizing selection bias and contamination
To avoid selection bias (during the recruitment process)
and potential contamination post-randomisation, GPs will
be generically informed that 1) the study targets the chal-
lenges of prescribing therapy in older patients and 2) what
participation entails in terms of time, resources, and re-
muneration; specific detail about the intervention (hypoth-
eses, CARAT) will be provided to Group A (intervention)
after GPs are randomly allocated (concealed allocation) to
minimise performance bias.
Although the gold-standard approach to evaluating be-
havioural interventions [34], it is inherently impossible
to achieve complete blinding in such CRTs as the inter-
vention cannot be masked [35,36]. Here, blinding is feas-
ible as follows:
 GPs will be blinded in part (ethically) to their
allocation status through the use of alternate
Recruit GPs from selected areas: Sydney
Metropolitan/Coastal/Regional -Urban/Regional-Rural





GPs identify ≥10 eligible patients each






Baseline Data Collection (GP / Project Officer)
ALL patients (demographics, medical history, risk factors) 
GP applies CARAT
(identify recommended therapy)
GP makes final decision re:  
antithrombotic therapy
Project Officer documents 
therapy prescribed by GP
Follow-up Data Collection (Project Officer)
ALL patients: 1, 6 and 12 months
via telephone interview, GP verification, hospital medical records
(Clinical outcomes, e.g., changes to therapy; stroke; bleed; risk factors; QoL)
12 months: 
GP applies CARAT again to review  
therapy in recruited patients
GP Feedback
Qualitative Data Collection 
(Satisfaction survey + Interview)
GP Interview
Qualitative Data Collection 
(Challenges in prescribing)
Optional ‘cross-over’ trial of CARAT 
(GP applies CARAT to 5 patients 
each)
Figure 1 Schematic outline of the main study.
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and “control”, and instead using ‘Group A’ or ‘Group
B’), thereby reducing performance bias.
 Researchers (Chief Investigators) will be blinded to
the allocation status of subjects during analyses (i.e.,
blinded assessment, e.g., PROBE design)
 project officers (i.e., the research assistants) will be
blinded to the initial allocation process (i.e., concealed
allocation of GPs will be independently undertaken by
the chief investigator) to minimise pre-randomisation
selection bias. However, the project officers will besubsequently unblinded to the different procedures
between study arms as they will necessarily liaise with
GPs in both arms to collect data and provide support
for the intervention (CARAT)
 assessment bias will be minimised by using common
objective and standardised data collection
instruments in both study arms and avoiding the
terms “intervention” and “control” (using Group A
or B) during recruitment and data collection
 patients will be blinded to the study allocation
(control versus intervention) of their GP; in
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will be informed of the specific study hypotheses re-
lating to monitoring therapy prescribed and clinical
outcomes over time.
In using the cluster-randomized trial design, contam-
ination within groups of GPs is minimized. Any con-
tamination between groups will be minimized through
specific screening during the recruitment process to ex-
clude those GPs practising across multiple (≥1) surger-
ies. Within ‘group’ practices (e.g., medical centres where
more than 1 GP is employed), all participating GPs will
be allocated to the same study arm (block randomisation).
Once allocated, drop-ins between arms and sharing of the
‘intervention (i.e., password protected CARAT) will not be
permitted.
Intervention Arm
The CARAT will be disseminated via a web-based inter-
face to GPs randomized to the intervention arm. Upon
recruitment, GPs will be given access to CARAT via log-
ins, passwords, together with supporting information
and on-site training by the project officer.
During routine clinical practice, GPs will utilize the
CARAT to support their decision-making processes in
selecting and/or reviewing antithrombotic therapy in their
patients. This will involve performing an individualized risk
assessment and generating a treatment recommendation
for their patient by carefully assessing relevant risk factors
for stroke, bleeding, medication misadventure and entering
this data, as guided by CARAT, into the web-based plat-
form. CARAT will then quantify the patient’s estimated risk
of stroke versus bleeding, flag pertinent medication man-
agement issues, and generate a recommendation for ther-
apy (warfarin, aspirin, none, other). Note: CARAT does
NOT require identifiable personal information to be entered
NOR is any information saved to the website.
The GP will consider the CARAT output and make a
final treatment decision to initiate, cease, or maintain
current antithrombotic therapy. Where the GP may dis-
agree with CARAT, the rationale for the decision will be
documented in the data collection process. Reviewed pa-
tients will be followed-up for up to 12 months to docu-
ment key clinical outcomes (i.e., strokes, bleeds).
Control Arm
GPs randomized into the control arm will follow their
usual care practices. They will review and select anti-
thrombotic therapy using their own clinical judgment,
processes and resources. At completion of the study (i.e.,
final patient follow-up period at 12 months is complete),
the GPs in the control arm will be given the opportunity
to trial the CARAT on 5 of their patients in their practice
setting (‘cross-over’ arm) to canvas feedback on the tool.Data collection
In addition to the output generated by CARAT, purpose-
designed data collection instruments (record forms, sur-
veys, questionnaires) will be used to extract and record
specific data (Table 1). Dedicated Project Officers will be
allocated to each participating division of general practice,
to coordinate the conduct of the study (i.e., participant re-
cruitment, implementation of intervention, data collec-
tion, provision of support to GPs) at each site.
Baseline data for patients and GPs will be collected by
the project officer within 48 hours of the index consult-
ation. During the baseline visit, the GP will apply CARAT
to consecutive admissions over a period of 3 months and
obtain the patient’s consent to participate. GPs will print-
out the completed risk-assessment template (generated by
the CARAT) for subsequent review by the project officer.
Each GP will then ‘flag’ the patient for review and baseline
data collection by the project officer by returning a
purpose-designed fax-back form with basic patient details.
Baseline data will be extracted from medical notes, patient
interview, and a brief patient survey.
Clinical outcome data will be collected at 1, 6 and up
to 12 months after the index consultation. This data will
be collected from patients via follow-up telephone inter-
view (15–20 minutes) by the project officer. To verify
outcomes, the GP will be contacted via phone and/or
the patient’s notes reviewed. Hospital medical records
may also be reviewed where patients have been admitted
for an acute event including a stroke or bleed.
A 1-month pilot study will be conducted prior to the
main trial to confirm project procedures/logistics.
Data analysis
Computerized data analysis will employ SPSS (Statistical
Package for the Social Sciences) Version 15. ANOVA will
test for differences in continuous variables. The Chi-
square test will examine differences in independent pro-
portions. Kappa analysis will detect the level of agreement
between prescribers’ clinical judgment and the CARAT
output. Logistic regression analysis will identify predictors
of clinical events (clotting versus bleeding), and selection
of antithrombotic therapy, accounting for the use of the
CARAT. Survival analysis will assess mortality rates in
both arms. All analyses will necessarily be based on the
ITT principle; standard imputation methods (e.g., last ob-
servation carried forward) will be used to estimate missing
data (withdrawal, failure to start) and data analysed ac-
cording to initial group (random) allocation. All analyses
will be adjusted for the effects of clustering, and set at a
significance (p) level of 0.05.
Outcomes measured
The primary outcome measures for the intervention will
include:
Table 1 Data collection items for GPs and patients
GPs Patients
• Demographics (age, gender) • Patient demographics
• Practice experience (years, specialty) • Medical history, co-morbidities, medication
• Practice site features (location, number of clients) • History of AF (duration, new onset or chronic)
• Decision-making processes (e.g., resources or processes normally used) • Risk factors for stroke (per CARAT)
• Agreement with CARAT recommendations (Intervention group) • Risk factors bleeding (per CARAT)
• Satisfaction with CARAT as a tool (Intervention group) • Quality of life (e.g., SF36)
• Barriers to prescribing therapy (ALL GPs) • Risk factors for medication misadventure [25]
• Current antithrombotic therapy utilised
• History of clotting and bleeding events
• Health services used to support therapy
• Health services used to support therapy
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made following application of CARAT;
 difference in the proportion of patients receiving no
therapy;
 overall difference in the proportion of patients
receiving antithrombotic therapy;
 difference in the proportion of patients receiving
warfarin therapy;
 difference in the proportion of patients experiencing
adverse clinical outcomes (ALL events).
The secondary outcome measures will include:
 the sustainability of prescribed therapy over time,
i.e., changes to antithrombotic therapy made during
patient follow-up up to 12 months;
 incidence of any clotting (thromboembolism, stroke)
events up to 12 months;
 incidence of any bleeding (minor or major
hemorrhage) events up to 12 months.
Qualitative data collection and analysis
Qualitative data is integral to this study; it will triangu-
late the findings regarding the utility and refinement of
CARAT for future sustainable implementation in general
practice (previous data focused on CARAT’s utility in
the acute care/hospital setting).
In-depth feedback will be obtained via individual face-
to-face or telephone interviews. A semi-structured process
will be adopted using a purpose-designed interview guide.
Initially, 5 to 10 GPs in each arm will be interviewed until
theme saturation is achieved. Each face-to-face interview
will be digitally-recorded, transcribed verbatim, and then
thematically analysed using inductive coding [37].
Discussion
The need for tailored sustainable interventions to optimize
the use of antithrombotic therapy for stroke prevention inat-risk patients is well documented [26], which will ultim-
ately reduce the considerable burden of stroke suffered by
individuals and the global community, on the background
of an ageing population. In this study, a novel decision-
support tool will be tested, to assist clinicians (specifically,
GPs) in their decision-making.
Given the expansion of the treatment armamentarium
following the development of the NOACs, the decision-
making will necessarily become more complex, and will
additionally be driven by the economic implications of the
potentially widespread use of newer, more expensive ther-
apies. This study specifically considers those therapies that
have been historically available in the local practice arena,
for which there is vast and robust evidence-base (i.e., war-
farin, aspirin). However, the findings of this study will
inform the need to integrate newer therapies, and their spe-
cific benefits and limitation, within decision-support tools.
Separate to evaluating the impact of this tool as a targeted
intervention, this study will additionally provide data on the
absolute and relative risks of clinical outcomes (e.g., changes
to therapy; stroke; bleeds; mortality) in an Australian
cohort of older persons with AF, and identify predictors of
these (e.g., risk factors, antithrombotics prescribed).
Our unique approach in this study addresses National
Research Priorities in Preventative Health and targets
major health issues in effective health care including an
ageing population, burden of chronic illness, and transla-
tion of evidence into practice. A key feature of this study
is that it targets the interface of patient care (general prac-
tice), addresses the at-risk population, and provides evi-
dence for the impact of the intervention by evaluating
related clinical outcomes. Its innovation lies in the applica-
tion of a novel computerized antithrombotic risk assess-
ment tool, developed by the researchers, to provide GPs
not only with a screening instrument, but importantly a
mechanism for comprehensive risk assessment that, for
the first time, quantifies the risk versus benefit of anti-
thrombotic therapy in individual patients. Eventually, the
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or other primary care services including Medication Re-
view and Disease State Management rendering its applica-
tion in practice highly sustainable.
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